Evans Syndrome Probably Secondary to BNT162b2 SARS-CoV-2 Vaccine: Case Report
SPMI CASE REPORTS · 14.11.2023
DOI: 10.60591/crspmi.170 ↗Kurz gefasst
Fallbericht in der Zeitschrift SPMI CASE REPORTS, erschienen am 14.11.2023. Verfasst von Silva und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Evans syndrome is a rare condition. There are few case reports of Evans syndrome following SARS-CoV-2 mRNA vaccine, none in Portugal. An eighteen-year-old male patient was admitted with abdominal pain, jaundice, dark urine, and fatigue. The evaluation performed was consistent with warm autoimmune hemolytic anemia, but he later developed autoimmune thrombocytopenia. His medical history was notable for IgA vasculitis at the age of 20 months and SARS--CoV-2 mRNA vaccination nine days before admission. Viral infections, autoimmune/lymphoproliferative diseases, immunodeficiencies, medications and thrombophilia were excluded. Although he did not initially respond to corticosteroids or immunoglobulin, he responded favorably to rituximab and cyclophosphamide. Given the temporal association and the exclusion of other causes, we can assume Evans syndrome probably secondary to SARS-CoV-2 mRNA vaccine. It is the first case in Portugal and describes a rare idiosyncrasy. It should not discourage vaccination at the population level.
Schlagwörter
Zitieren
APA
Silva, Inês, Silva, R. C., Sopa, I., Gregório, Catarina, & Peixoto, L. (2023). Evans Syndrome Probably Secondary to BNT162b2 SARS-CoV-2 Vaccine: Case Report. SPMI CASE REPORTS. https://doi.org/10.60591/crspmi.170
Vancouver
Silva, Inês, Silva RC, Sopa I, Gregório, Catarina, et al. Evans Syndrome Probably Secondary to BNT162b2 SARS-CoV-2 Vaccine: Case Report. SPMI CASE REPORTS. 2023. doi:10.60591/crspmi.170
BibTeX
@article{Silva2023,
author = {Silva and Inês and Silva, Ryan Costa and Sopa, Inês and Gregório and Catarina and Peixoto, Lígia},
title = {Evans Syndrome Probably Secondary to BNT162b2 SARS-CoV-2 Vaccine: Case Report},
journal = {SPMI CASE REPORTS},
year = {2023},
doi = {10.60591/crspmi.170}
}
EUVIMED